BioSpace News Archive

Substance abuse monitoring post-recovery, including for alcoholics, needs constant self-discipline and accountability for enforcing the correct behavior.

Nippon Express Italia S.P.A. obtained Good Distribution Practice (GDP) certification from the certification body CERTIQUALITY S.r.l., effective May 25 , for its company-owned warehouse near Milan Malpensa Airport, evidencing its compliance with GDP standards for the proper distribution of pharmaceuticals established by the European Commission.

Qualigen Therapeutics, Inc. announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Qualigen’s QN-165 with an initial target indication for the treatment of COVID-19 in hospitalized patients.

Wesana Health Holdings Inc. today announced the addition of Ian Burnstein to its Scientific Advisory Board.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that data from its clinical development program for TAVALISSE® (fostamatinib disodium hexahydrate) tablets will be highlighted in two presentations at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress, taking place online from July 17 – 21, 2021.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 5, 2021, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended June 30, 2021.

VistaMed is pleased to announce that they are part of a team that has been awarded €5.1 million over a three-year period for a project that aims to provide the first catheter to deliver direct 3D, intraprocedural analysis of the success of cardiac ablation, in the treatment of atrial fibrillation.

Anticancer Bioscience, pioneers in synthetic lethal approaches to precision oncology, announced appointment of Dr. Hong Liu as VP of Clinical Development.

Asensus Surgical, Inc., a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced that it has filed a 510 submission with the FDA for an expansion of capabilities on the previously cleared Intelligent Surgical Unit™.

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021 after the market closes.